The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL

Abstract Background Dyslipidaemia is a major contributor to the increased risk of cardiovascular disease (CVD) associated with type 2 diabetes (T2D). This study aimed to characterize the extent of lipid-lowering therapy use and its impact on lipid and glycaemic outcomes in people with T2D uncontroll...

Full description

Bibliographic Details
Main Authors: Markolf Hanefeld, Louise Traylor, Ling Gao, Wolfgang Landgraf
Format: Article
Language:English
Published: BMC 2017-05-01
Series:Cardiovascular Diabetology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12933-017-0548-0